Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CANAKINUMAB Cause Helicobacter infection? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Helicobacter infection have been filed in association with CANAKINUMAB (Ilaris). This represents 0.1% of all adverse event reports for CANAKINUMAB.

6
Reports of Helicobacter infection with CANAKINUMAB
0.1%
of all CANAKINUMAB reports
2
Deaths
4
Hospitalizations

How Dangerous Is Helicobacter infection From CANAKINUMAB?

Of the 6 reports, 2 (33.3%) resulted in death, 4 (66.7%) required hospitalization, and 2 (33.3%) were considered life-threatening.

Is Helicobacter infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CANAKINUMAB. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does CANAKINUMAB Cause?

Pyrexia (1,327) Inappropriate schedule of drug administration (1,238) Drug ineffective (1,078) Inappropriate schedule of product administration (944) Pain (858) Condition aggravated (771) Malaise (684) Off label use (557) Arthralgia (555) Rash (505)

What Other Drugs Cause Helicobacter infection?

METHOTREXATE (4,356) ABATACEPT (4,333) ADALIMUMAB (4,297) TOCILIZUMAB (4,272) RITUXIMAB (4,249) LEFLUNOMIDE (4,236) CETIRIZINE (4,078) FOLIC ACID (4,075) INFLIXIMAB (4,064) PREDNISONE (4,040)

Which CANAKINUMAB Alternatives Have Lower Helicobacter infection Risk?

CANAKINUMAB vs CANDESARTAN CANAKINUMAB vs CANDESARTAN CILEXETIL CANAKINUMAB vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE CANAKINUMAB vs CANGRELOR CANAKINUMAB vs CANIS LUPUS FAMILIARIS SKIN

Related Pages

CANAKINUMAB Full Profile All Helicobacter infection Reports All Drugs Causing Helicobacter infection CANAKINUMAB Demographics